7th Annual MarketsandMarkets

Next-Gen Immuno-Oncology Conference

20th - 21st June 2024

Hilton Boston Logan Airport, One Drive, Boston, MA 02128, USA

Our 7th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 20th - 21st June 2024, in Hilton Boston Logan Airport, One Drive, Boston, MA 02128, USA would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in the development of ADCs, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccine development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in the development of ADCs, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy

CO-LOCATED CONFERENCES

2nd Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference - East Coast Edition

WHAT TO EXPECT

  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Biomarkers and Personalized Medicine in IO
  • CAR-T Cell therapy, TCR Based-Cell Therapy
  • Tumor microenvironment and Oncolytic Viruses

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Session

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors

CONFERENCE AGENDA

Registration

08:15 - 08:55

Opening Remarks from the Chairperson

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

08:55 - 09:00

Keynote Presentation - Anchored Immunotherapy as a Better Approach for Delivery of Immuno-oncology Agents

Howard Kaufman

Howard Kaufman, President and CEO, Lecturer, Ankyra Therapeutics, Harvard Medical School

09:00 - 09:30

Landscape change in melanoma immunotherapy. Déjà vu or revolution?

09:30 - 10:00

Enhanced Multiplex IHC Technology for Precision Oncology

Aurélie Auguste

Aurélie Auguste, Director, Translational Data Analysis, Veracyte

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Enhanced Multiplex IHC Technology for Precision Oncology

Aurélie Auguste

Aurélie Auguste, Director, Translational Data Analysis, Veracyte

11:15 - 11:45

SUPLEXA therapeutic cells, a clinically derisked cell therapy platform with unique mechanisms of action for treating solid cancers

Frank Borriello

Frank Borriello, Founder and CEO, Alloplex Biotherapeutics

11:45 - 12:15

Development of methylation and mutation panel for colorectal cancer

Collin Hudzik

Collin Hudzik, Scientist, EpigenDx

12:15 - 12:45

Next generation translational research platforms for cell therapy in cancer

Aaron Goldman

Aaron Goldman, Faculty and Instructor in Medicine, Harvard Medical School

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Challenges and Opportunities in Validating Preclinical Models for Immuno-Oncology Drug Development

Dr. Leena Gandhi

Dr. Leena Gandhi, Chief Medical Officer, NextPoint Therapeutics

14:15 - 14:45

Immune stimulation of myeloid cells for cancer therapy

Christopher Garris

Christopher Garris, Assistant Professor of Pathology, Massachusetts General Hospital, Harvard Medical School

14:45 - 15:15

Preliminary results of a Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.

Roger Waltzman

Roger Waltzman, Chief Medical Officer, Indaptus Therapeutics

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Enhancing TCR-T Activity for Solid Tumors through Synthetic Biology and Gene Editing

Allison Drain

Allison Drain, Preclinical Development, Affini-T Therapeutics

16:30 - 17:00

Adverse Events and Safety Management: Review potential side effects of immunotherapies and best practices for managing them.

17:00 - 17:30

Closing Remarks from the Chairperson

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

17:30 - 17:30

Registration

08:15 - 08:55

Opening Remarks from the Chairperson

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

08:55 - 09:00

Challenges and Opportunities for the development of ADCs, bispecific immunomodulatory therapies, and combination

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

09:00 - 09:30

ProtoNKTM Cells from Pluripotent Stem Cells: Therapeutics for All Patients

Allen Feng

Allen Feng, Founder and Chief Scientific Officer, HebeCell Corporation

09:30 - 10:00

Tumour microenvironment, cancer stem cells, polyploid giant cells

Shriya Joshi

Shriya Joshi, Scientist, small molecule drug discovery, Bristol Myers Squibb

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Presentation

Benjamin Brown

Benjamin Brown, Co-Founder & Executive Director, American Society of Pharmacovigilance

11:15 - 11:45

Novel antibody-enabled targeted protein stabilization (TPS2) that augments anti-tumor immune response by delivering Cbl-b inhibitor to immune cells while blocking checkpoint molecule, PD1

Joanne Lim

Joanne Lim, Associate Director, Immunology, Orum Therapeutics

11:45 - 12:15

Liquid biopsy – a step closer to realizing the power of precision oncology

Raluca Budiu-Predoiu

Raluca Budiu-Predoiu, Director, Companion Diagnostics Strategy Lead, , Abbvie

12:15 - 12:45

Combination Strategies to Overcome Resistance to Anti-PD-1/PD-L1 Therapies

Chakravarthy Garlapati

Chakravarthy Garlapati, Senior Scientist, (Molecular and Cell Pharmacology), Alkermes

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Future opportunities in clinical development of ICI’s

Takami Sato

Takami Sato, Professor of Medical Oncology Research Director, Thomas Jefferson University

Aaron Goldman

Aaron Goldman, Faculty and Instructor in Medicine, Harvard Medical School

Howard Kaufman

Howard Kaufman, President and CEO, Lecturer, Ankyra Therapeutics, Harvard Medical School

Shriya Joshi

Shriya Joshi, Scientist, small molecule drug discovery, Bristol Myers Squibb

14:15 - 14:45

Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care

Takami Sato

Takami Sato, Professor of Medical Oncology Research Director, Thomas Jefferson University

Shi-Jiang (John) Lu

Shi-Jiang (John) Lu, President and CEO, HebeCell Corporation

Aaron Goldman

Aaron Goldman, Faculty and Instructor in Medicine, Harvard Medical School

14:45 - 15:30

Closing Remarks from the Chairperson

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

15:30 - 15:30

SPEAKERS

Aaron Goldman

Aaron Goldman

Faculty and Instructor in Medicine, Harvard Medical School

Lanye Huang

Lanye Huang

Business Development Executive/ Senior BD Manager, SanyouBio

Allen Feng

Allen Feng

Founder and Chief Scientific Officer, HebeCell Corporation

Chakravarthy Garlapati

Chakravarthy Garlapati

Senior Scientist, (Molecular and Cell Pharmacology), Alkermes

Tony Arulanandam

Tony Arulanandam

SVP and Head of Research and Development, Cytovia Therapeutics

Shriya Joshi

Shriya Joshi

Scientist, small molecule drug discovery, Bristol Myers Squibb

Collin Hudzik

Collin Hudzik

Scientist, EpigenDx

Allison Drain

Allison Drain

Preclinical Development, Affini-T Therapeutics

Howard Kaufman

Howard Kaufman

President and CEO, Lecturer, Ankyra Therapeutics, Harvard Medical School

Raluca Budiu-Predoiu

Raluca Budiu-Predoiu

Director, Companion Diagnostics Strategy Lead, , Abbvie

Dr. Leena Gandhi

Dr. Leena Gandhi

Chief Medical Officer, NextPoint Therapeutics

Roger Waltzman

Roger Waltzman

Chief Medical Officer, Indaptus Therapeutics

Anu Santhanagopal

Anu Santhanagopal

Head US Oncology Medical Affairs Strategy, Boehringer Ingelheim

Christopher Garris

Christopher Garris

Assistant Professor of Pathology, Massachusetts General Hospital, Harvard Medical School

Frank Borriello

Frank Borriello

Founder and CEO, Alloplex Biotherapeutics

Rakesh Dixit

Rakesh Dixit

CEO, Bionavigen

Aurélie Auguste

Aurélie Auguste

Director, Translational Data Analysis, Veracyte

ENQUIRE NOW

SPONSORS

LOCATION

Venue

Hilton Boston Logan Airport, One Drive, Boston, MA 02128, USA

PAST EVENT GALLERY